Rimegepant
Mar 24, 2020
Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid
Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020. The company has been acquirin...
Read More...
Nov 28, 2017
Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial
Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
